Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

As previously reported on the Current Report on Form 8-K (the "Original Filing") filed by Albireo Pharma, Inc. (the "Company") on August 8, 2022, the Company's Board of Directors (the "Board") elected Susan Alesina and Habib Dable as directors of the Company, effective as of August 8, 2022.

At the time of the Original Filing, the Board had not made a determination regarding any committee assignments for Ms. Alesina or Mr. Dable. This amended Current Report on Form 8-K is being filed to provide the committee assignment information omitted from the Original Filing. On August 19, 2022, the Board appointed Ms. Alesina to the Audit Committee of the Board and appointed Mr. Dable to the Compensation Committee of the Board, effective immediately.

Other than the preceding disclosure, no other disclosure reported in the Original Filing is amended pursuant to this Report.

© Edgar Online, source Glimpses